Ramanathan R C, A'Hern R, Fisher C, Thomas J M
Department of Surgical Oncology, University of Pittsburgh Medical Center, PA 15213, USA.
Ann Surg Oncol. 1999 Jan-Feb;6(1):57-69. doi: 10.1007/s10434-999-0057-9.
The establishment of a universally acceptable staging system for soft tissue sarcomas has been hampered by the low incidence, various grading systems, and lack of consensus regarding the value of different prognostic factors. We aimed to evaluate prognostic factors in patients with extremity soft tissue sarcomas and to test the validity of the AJCC/UICC staging system.
Prospectively collected data from 316 previously untreated patients with primary extremity soft tissue sarcomas treated at a single institution between 1989 and 1995 were studied. The influence of clinical and pathological factors on local recurrence, distant metastasis, and disease-specific survival was analyzed by univariate and multivariate techniques.
Large tumor size and high histological grade were independent adverse prognostic factors for distant metastasis. Large size, high grade, and positive microscopic surgical margins were independent adverse prognostic factors, and liposarcoma histology was an independent favorable prognostic factor for disease-specific survival. Within each histological grade, there was a progressive decline in survival with increasing tumor size, as reflected by an almost linear increase in hazard ratios. Similarly, there was a progressive fall in survival with increasing grade within each size group (<5 cm, 5 to 10 cm, 10 to 15 cm, and > 15 cm). AJCC staging did not correlate well with prognosis. Survival for intermediate-grade tumors smaller than 5 cm (stage IIA) was better than that for low-grade tumors larger than 5 cm (stage IB) (86% vs. 73%). Survival for high-grade tumors smaller than 5 cm (stage IIIA) was better than that for intermediate-grade tumors larger than 5 cm (stage IIB) (72% vs. 57%). A modified staging system was formulated based on the additive influence of size and grade on the estimated hazard ratios for disease-specific survival, as follows: stage IA, G1T1; stage IB, G1T2 or G2T1; stage IIA, G1T3 or G2T2 or G3T1; stage IIB, G1T4 or G2T3 or G3T2; stage IIIA, G2T4 or G3T3; stage IIIB, G3T4; and stage IV, M1 (G1, G2, G3 = low, intermediate, and high grade; T1, T2, T3, T4 = tumor size < 5 cm, 5-10 cm, 10-15 cm, and > 15 cm, respectively). The 5-year disease-specific survivals of stages IA, IB, IIA, IIB, IIIA, and IIIB were 100%, 83%, 74%, 61%, 39%, and 18%, respectively. The 5-year disease-specific survival for stages I, II, III, and IV were 90%, 67%, 31%, and 6% respectively. The survival difference between each stage was statistically significant (P < .001).
Histological grade and tumor size are equally important determinants of distant metastases and survival. The AJCC/UICC staging system is based primarily on the grade of the tumor, with size used to subgroup each stage. A staging system for extremity soft tissue sarcomas with equal emphasis on grade and size is proposed that correlates extremely well with prognosis.
软组织肉瘤普遍适用的分期系统的建立受到发病率低、多种分级系统以及不同预后因素价值缺乏共识的阻碍。我们旨在评估肢体软组织肉瘤患者的预后因素,并检验美国癌症联合委员会(AJCC)/国际抗癌联盟(UICC)分期系统的有效性。
对1989年至1995年在单一机构接受治疗的316例未经治疗的原发性肢体软组织肉瘤患者的前瞻性收集数据进行研究。通过单因素和多因素技术分析临床和病理因素对局部复发、远处转移和疾病特异性生存的影响。
肿瘤体积大及组织学分级高是远处转移的独立不良预后因素。肿瘤体积大、分级高及手术切缘显微镜下阳性是独立的不良预后因素,脂肪肉瘤组织学类型是疾病特异性生存的独立有利预后因素。在每个组织学分级内,随着肿瘤体积增大生存率逐渐下降,风险比几乎呈线性增加反映了这一点。同样,在每个体积组(<5 cm、5至10 cm、10至15 cm和>15 cm)内,随着分级增加生存率逐渐下降。AJCC分期与预后的相关性不佳。小于5 cm的中级肿瘤(IIA期)的生存率优于大于5 cm的低级肿瘤(IB期)(86%对73%)。小于5 cm的高级肿瘤(IIIA期)的生存率优于大于5 cm的中级肿瘤(IIB期)(72%对57%)。基于肿瘤大小和分级对疾病特异性生存估计风险比的累加影响制定了改良分期系统,如下:IA期,G1T1;IB期,G1T2或G2T1;IIA期,G1T3或G2T2或G3T1;IIB期,G1T4或G2T3或G3T2;IIIA期,G2T4或G3T3;IIIB期,G3T4;IV期,M1(G1、G2、G3 = 低、中、高级;T1、T2、T3、T4 = 肿瘤大小分别<5 cm、5至10 cm、10至15 cm和>15 cm)。IA期、IB期、IIA期、IIB期、IIIA期和IIIB期的5年疾病特异性生存率分别为100%、83%、74%、61%、39%和18%。I期、II期、III期和IV期的5年疾病特异性生存率分别为90%、67%、31%和6%。各期之间的生存差异具有统计学意义(P <.001)。
组织学分级和肿瘤大小是远处转移和生存的同等重要决定因素。AJCC/UICC分期系统主要基于肿瘤分级,用大小对每个分期进行亚组划分。提出了一个对肢体软组织肉瘤分级和大小同等重视的分期系统,该系统与预后的相关性非常好。